{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:29:37Z","timestamp":1778261377569,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hubei Province Health and Family Planning Scientific Research Project","award":["WJ2018H178"],"award-info":[{"award-number":["WJ2018H178"]}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"crossref","award":["2019CFB567"],"award-info":[{"award-number":["2019CFB567"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Municipal Commission of Health and Family Planning","award":["201940476"],"award-info":[{"award-number":["201940476"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Fusarium<\/jats:italic> species are the fungal pathogens most commonly responsible for the mycotic keratitis, which are resistant to the majority of currently available antifungal agents. The present study was designed to assess the efficacy of a combination of low doses chlorhexidine with two other commonly used drugs (voriconazole and natamycin) to treat <jats:italic>Fusarium<\/jats:italic> infections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We utilized combinations of chlorhexidine and natamycin or voriconazole against 20 clinical <jats:italic>Fusarium<\/jats:italic> strains in vitro using a checkerboard-based microdilution strategy. In order to more fully understand the synergistic interactions between voriconazole and chlorhexidine, we utilized a <jats:italic>Galleria mellonella<\/jats:italic> model to confirm the combined antifungal efficacy of chlorhexidine and voriconazole in vivo. We found that for voriconazole, natamycin, and chlorhexidine as single agents, the minimum inhibitory concentration (MIC) ranges were 2\u20138, 4\u201316, and\u2009&gt;\u200916\u2009\u03bcg\/ml, respectively. In contrast, the MIC values for voriconazole and chlorhexidine were reduced to 0.25\u20131 and 1\u20132\u2009\u03bcg\/ml, respectively, when these agents were administered in combination, with synergy being observed for 90% of tested <jats:italic>Fusarium<\/jats:italic> strains. Combined chlorhexidine and natamycin treatment, in contrast, exhibited synergistic activity for only 10% of tested <jats:italic>Fusarium<\/jats:italic> strains. We observed no evidence of antagonism. Our in vivo model results further confirmed the synergistic antifungal activity of chlorhexidine and voriconazole.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results offer novel evidence that voriconazole and chlorhexidine exhibit synergistic activity when used to suppress the growth of <jats:italic>Fusarium<\/jats:italic> spp., and these agents may thus offer value as a combination topical antifungal treatment strategy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12866-020-01960-y","type":"journal-article","created":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T06:02:53Z","timestamp":1599285773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The combined utilization of Chlorhexidine and Voriconazole or Natamycin to combat Fusarium infections"],"prefix":"10.1186","volume":"20","author":[{"given":"Tao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-2682","authenticated-orcid":false,"given":"Jingwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianjuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,5]]},"reference":[{"issue":"12","key":"1960_CR1","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/myc.12822","volume":"61","author":"S Mahmoudi","year":"2018","unstructured":"Mahmoudi S, Masoomi A, Ahmadikia K, Tabatabaei SA, Soleimani M, Rezaie S, Ghahvechian H, Banafsheafshan A. Fungal keratitis: an overview of clinical and laboratory aspects. Mycoses. 2018;61(12):916\u201330.","journal-title":"Mycoses."},{"issue":"5","key":"1960_CR2","first-page":"644","volume":"97","author":"O Fekih","year":"2019","unstructured":"Fekih O, Haj Said O, Zgolli HM, Mabrouk S, Bakir K, Nacef L. Microbiologic profile of the mycosic absess on a reference center in Tunisia. Tunis Med. 2019;97(5):644\u20139.","journal-title":"Tunis Med"},{"issue":"11","key":"1960_CR3","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.ophtha.2017.05.012","volume":"124","author":"A Austin","year":"2017","unstructured":"Austin A, Lietman T, Rose-Nussbaumer J. Update on the Management of Infectious Keratitis. Ophthalmology. 2017;124(11):1678\u201389.","journal-title":"Ophthalmology."},{"issue":"9","key":"1960_CR4","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/bjophthalmol-2014-306485","volume":"99","author":"S Sharma","year":"2015","unstructured":"Sharma S, Das S, Virdi A, Fernandes M, Sahu SK, Kumar Koday N, Ali MH, Garg P, Motukupally SR. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial. Br J Ophthalmol. 2015;99(9):1190\u20135.","journal-title":"Br J Ophthalmol"},{"key":"1960_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fcimb.2020.00133","volume":"10","author":"C Oliveira Dos Santos","year":"2020","unstructured":"Oliveira Dos Santos C, Kolwijck E, van Rooij J, Stoutenbeek R, Visser N, Cheng YY, NTY S, Verweij PE, Eggink CA. Epidemiology and Clinical Management of Fusarium keratitis in the Netherlands, 2005\u20132016. Front Cell Infect Microbiol. 2020;10:133.","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"1960_CR6","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1097\/IAE.0000000000001800","volume":"38","author":"C Oakley","year":"2018","unstructured":"Oakley C, Allen P, Hooshmand J, BJT V. Pain and antisepsis after ocular administration of povidone-iodine versus chlorhexidine. Retina. 2018;38(10):2064\u20136.","journal-title":"Retina"},{"issue":"8","key":"1960_CR7","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1111\/aos.12981","volume":"94","author":"CL Oakley","year":"2016","unstructured":"Oakley CL, Vote BJ. Aqueous chlorhexidine (0.1%) is an effective alternative to povidone-iodine for intravitreal injection prophylaxis. Acta Ophthalmol. 2016;94(8):e808\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"16","key":"1960_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.5435\/JAAOS-D-18-00105","volume":"27","author":"J Letzelter","year":"2019","unstructured":"Letzelter J, Hill JB, Hacquebord J. An overview of skin antiseptics used in Orthopaedic surgery procedures. J Am Acad Orthop Surg. 2019;27(16):599\u2013606.","journal-title":"J Am Acad Orthop Surg"},{"key":"1960_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.archoralbio.2018.02.009","volume":"89","author":"E Scheibler","year":"2018","unstructured":"Scheibler E, da Silva RM, Leite CE, Campos MM, Figueiredo MA, Salum FG, Cherubini K. Stability and efficacy of combined nystatin and chlorhexidine against suspensions and biofilms of Candida albicans. Arch Oral Biol. 2018;89:70\u20136.","journal-title":"Arch Oral Biol"},{"issue":"6","key":"1960_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1128\/AAC.26.6.793","volume":"26","author":"MB Hamill","year":"1984","unstructured":"Hamill MB, Osato MS, Wilhelmus KR. Experimental evaluation of chlorhexidine gluconate for ocular antisepsis. Antimicrob Agents Chemother. 1984;26(6):793\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1960_CR11","doi-asserted-by":"publisher","first-page":"e02669","DOI":"10.1128\/AAC.02669-18","volume":"63","author":"C Oliveira Dos Santos","year":"2019","unstructured":"Oliveira Dos Santos C, Kolwijck E, van der Lee HA, Tehupeiory-Kooreman MC, Al-Hatmi AMS, Matayan E, Burton MJ, Eggink CA, Verweij PE. In Vitro activity of Chlorhexidine compared with seven antifungal agents against 98 Fusarium isolates recovered from fungal keratitis patients. Antimicrob Agents Chemother. 2019;63(8):e02669\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1960_CR12","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1097\/OPX.0000000000000407","volume":"91","author":"Y Xu","year":"2014","unstructured":"Xu Y, He Y, Zhou L, Gao C, Sun S, Wang X, Pang G. Effects of contact lens solution disinfectants against filamentous fungi. Optom Vis Sci. 2014;91(12):1440\u20135.","journal-title":"Optom Vis Sci"},{"issue":"3","key":"1960_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3109\/09286589709115721","volume":"4","author":"MR Rahman","year":"1997","unstructured":"Rahman MR, Minassian DC, Srinivasan M, Martin MJ, Johnson GJ. Trial of chlorhexidine gluconate for fungal corneal ulcers. Ophthalmic Epidemiol. 1997;4(3):141\u20139.","journal-title":"Ophthalmic Epidemiol"},{"issue":"8","key":"1960_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/bjo.82.8.919","volume":"82","author":"MR Rahman","year":"1998","unstructured":"Rahman MR, Johnson GJ, Husain R, Howlader SA, Minassian DC. Randomised trial of 0.2% chlorhexidine gluconate and 2.5% natamycin for fungal keratitis in Bangladesh. Br J Ophthalmol. 1998;82(8):919\u201325.","journal-title":"Br J Ophthalmol"},{"key":"1960_CR15","first-page":"CD004241","volume":"4","author":"NV FlorCruz","year":"2015","unstructured":"FlorCruz NV, Evans JR. Medical interventions for fungal keratitis. Cochrane Database Syst Rev. 2015;4:CD004241.","journal-title":"Cochrane Database Syst Rev"},{"key":"1960_CR16","doi-asserted-by":"crossref","unstructured":"Boral H, van Diepeningen A, Erdem E, Yagmur M, de Hoog GS, Ilkit M, Meis JF, Al-Hatmi AMS. Mycotic keratitis caused by Fusarium solani sensu stricto (FSSC5): a case series. Mycopathologia. 2018;183(5):835\u201340.","DOI":"10.1007\/s11046-018-0280-7"},{"issue":"2","key":"1960_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.funbio.2015.06.002","volume":"120","author":"U Binder","year":"2016","unstructured":"Binder U, Maurer E, Lass-Fl\u00f6rl C. Galleria mellonella: an invertebrate model to study pathogenicity in correctly defined fungal species. Fungal Biol. 2016;120(2):288\u201395.","journal-title":"Fungal Biol"},{"issue":"1","key":"1960_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/jof5010003","volume":"5","author":"N Trevijano-Contador","year":"2018","unstructured":"Trevijano-Contador N, Zaragoza O. Immune response of Galleria mellonella against human fungal pathogens. J Fungi (Basel). 2018;5(1):3.","journal-title":"J Fungi (Basel)"},{"issue":"2","key":"1960_CR19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1590\/S1517-83822012000200047","volume":"43","author":"KI Teixeira","year":"2012","unstructured":"Teixeira KI, Ara\u00fajo PV, Sinisterra RD, Cort\u00e9s ME. Chlorhexidine: beta-cyclodextrin inhibits yeast growth by extraction of ergosterol. Braz J Microbiol. 2012;43(2):810\u20138.","journal-title":"Braz J Microbiol"},{"issue":"6","key":"1960_CR20","first-page":"658","volume":"71","author":"H Salah","year":"2015","unstructured":"Salah H, Al-Hatmi AM, Theelen B, Abukamar M, Hashim S, van Diepeningen AD, Lass-Florl C, Boekhout T, Almaslamani M, Taj-Aldeen SJ. Phylogenetic diversity of human pathogenic Fusarium and emergence of uncommon virulent species. J Inf Secur. 2015;71(6):658\u201366.","journal-title":"J Inf Secur"},{"issue":"16","key":"1960_CR21","first-page":"1","volume":"28","author":"H John","year":"2008","unstructured":"John H. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard. M38-A2. Clin Lab Stand Inst. 2008;28(16):1\u201335.","journal-title":"Clin Lab Stand Inst"},{"issue":"1","key":"1960_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","volume":"52","author":"FC Odds","year":"2003","unstructured":"Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1\u20131.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-020-01960-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-020-01960-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-020-01960-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T23:09:16Z","timestamp":1630796956000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-020-01960-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,5]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1960"],"URL":"https:\/\/doi.org\/10.1186\/s12866-020-01960-y","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,5]]},"assertion":[{"value":"6 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}